PD-1/VEGF antibody is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Lepu Biopharma Co., Ltd. (1) and Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1). Registered phases: Phase 1/2 and Phase EARLY_PHASE1. Conditions studied include Advanced Colorectal Cancer; Advanced Lung Cancer; Lung Metastasis.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06928922 | Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. (ClinicalTrials.gov ↗) Advanced Lung Cancer, Lung Metastasis |
Phase EARLY_PHASE1 | Recruiting |
| NCT07737600 | A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer (ClinicalTrials.gov ↗) Advanced Colorectal Cancer |
Phase 1/2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Colorectal Cancer | 1 |
| Advanced Lung Cancer | 1 |
| Lung Metastasis | 1 |
| Lead sponsor | Trials |
|---|---|
| Lepu Biopharma Co., Ltd. | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Register | PD-1/VEGF antibody trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PD-1/VEGF antibody works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PD-1/VEGF antibody (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.